Ulcerative Colitis Clinical Trials

Showing 7501-7520 of 9,572 trials

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

NCT03104621

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and preservative-free 0.0015% tafluprost will reduce intraocular pressure significantly. In addition, preservative-free 0.0015% tafluprost might improve tolerability of glaucoma patients.

Primary Open-angle Glaucoma

Gangnam Severance Hospital20 participantsStarted Mar 2013

COMPLETEDPhase 2

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106

This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug. This study will also test whether QPI-1007, injected into the eye, helps prevent both structural damage of the nerve tissue in the eye and the loss of visual function in subjects with acute primary angle-closure glaucoma.

Glaucoma, Angle-closure, Primary, Acute

Quark Pharmaceuticals46 participantsStarted Dec 2013

Orange, California, United States • Pasadena, California, United States • Houston, Texas, United States +5 more locations

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Related Searches

Postoperative Complications in Patients With Obesity Hypoventilation Syndrome

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

Leg Fluid Shift in Patients With Chronic Heart Failure and Obstructive or Central Sleep Apnea

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension

Translating The GOLD COPD Guidelines Into Primary Care Practice

Study of Effects of L-Arginine in Colitis and Colon Cancer

Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

Closed Reduction With Anesthesia and no Anesthesia for Developmental Dislocation of the Hip < 6 Months

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

Regional Changes in Upper Limb Perfusion Following Brachial Plexus Block: A Pilot Study

The Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure on Appearance and Age

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Flutiform® Compared With Seretide® in the Treatment of COPD

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)